Impact of the influenza vaccination on cancer patients undergoing therapy with immune checkpoint inhibitors (ICI).

Gopalakrishnan, Ragisha; Johnson, Douglas B.; York, Sally J.; Neuss, Michael N.; Osterman, Travis; Chism, David D.; Ancell, Kristin K.; Mayer, Ingrid A.; Abramson, Vandana G.; Levy, Mia A.; Wyman, Kenneth; Gilbert, Jill; Reddy, Nishita; Morgan, David S.; Rathmell, Kimryn; Horn, Leora

doi:10.1200/jco.2018.36.15_suppl.3053

Cited by 11 publications

(25 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of three subsequent retrospective analyses about the impact of the vaccine on the outcome of cancer patient treated with immunotherapy, were reported at the 2017 and 2018 annual meeting of the American Society of Clinical Oncology (ASCO). Some of their results confirmed, as it was in the INVIDIa study, an improvement in OS in vaccinated patients, regardless of the clinical efficacy of the vaccine, which was not specifically tested [19][20][21].…”

Section: Retrospective Studiesmentioning

confidence: 71%

State of the art about influenza vaccination for advanced cancer patients receiving immune checkpoint inhibitors: When common sense is not enough

Bersanelli

Buti

Giorgi

et al. 2019

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Influenza vaccination is recommended for advanced cancer patients, since impaired immunity is presumed to be due not only to the tumor itself but also to immunosuppressive treatments, such as chemotherapy and radiotherapy. The recent advances in the systemic management of metastatic solid tumors, with the introduction of immune checkpoint inhibitors for several indications in clinical practice, has re-actualized simple clinical issues, such as the vaccinal recommendations and counseling, for which common sense is not enough to support pragmatic choices. In the present review, we summarized the evidence about influenza vaccine administration during immune checkpoint blockade, emphasizing the need of prospective data to definitely guide our advices to a growing group of cancer patients.

show abstract

Section: Retrospective Studiesmentioning

confidence: 71%

State of the art about influenza vaccination for advanced cancer patients receiving immune checkpoint inhibitors: When common sense is not enough

Bersanelli

Buti

Giorgi

et al. 2019

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

show abstract

“…However, a lower incidence of pneumonitis was observed in vaccinated patients compared to unvaccinated patients, supporting the use of IIV in this patient population. 7 In our data, a notable difference was observed when comparing duration of ICI therapy between patients who experienced imAEs and those who did not.…”

Section: Discussionmentioning

confidence: 57%

“…In addition to our case series, several studies have been published in abstract/poster or full manuscript form over the previous 12 months (Table 5). [7][8][9][10] Vaccine efficacy has been evaluated in ICI patient populations as well. In a phase II trial, most vaccinated patients who were receiving ipilimumab demonstrated increased antibody levels to influenza B, A/H1N1/H3H2 antigens compared to nonvaccinated patients, suggesting that an appropriate immunization response can be achieved in patients receiving CTLA-4 inhibitors.…”

Section: Discussionmentioning

confidence: 99%

“…6 Until recently, there has been a scarcity of information investigating concurrent ICI therapy with the administration of influenza vaccination. [7][8][9][10] Ipilimumab, a fully humanized monoclonal antibody that blocks CTLA-4, has demonstrated improved survival in metastatic melanoma. 11 Similarly, the PD-1/ PD-L1 inhibitors, either alone or in combination with ipilimumab, have significantly improved patient survival and outcomes in numerous solid tumor malignancies.…”

Section: Introductionmentioning

confidence: 99%

“…However, a larger retrospective study (n ¼ 534), recently presented at the 2018 American Society of Clinical Oncology Annual Meeting, did not report worsening imAEs in the cohort of patients who were treated with immunotherapy and vaccination. 7 Our prospective study was designed to further evaluate the potential increase in incidence of imAEs secondary to inactivated influenza vaccination (IIV) in patients receiving these immunotherapy agents as well as elucidate potential systemic cytokine or chemokine changes.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Immune-mediated adverse events following influenza vaccine in cancer patients receiving immune checkpoint inhibitors

Gwynn¹,

DeRemer

Saunders

et al. 2019

J Oncol Pharm Pract

View full text Add to dashboard Cite

Objectives The emergence of immune checkpoint inhibitors has transformed treatment paradigms for various malignancies. Patients with cancer are at increased risk of complications and hospitalizations from influenza; therefore, it is recommended that they receive inactivated influenza vaccination. However, efficacy and safety of inactivated influenza vaccination in patients receiving immune checkpoint inhibitors is uncertain. The objective of this prospective case series was to evaluate the incidence of immune-mediated adverse events (imAEs) following inactivated influenza vaccination in patients receiving immune checkpoint inhibitors. Changes in cytokine and chemokine levels were also evaluated. Methods Patients receiving immune checkpoint inhibitors during the 2017–2018 influenza season were eligible for study participation. Peripheral blood samples were collected prior to administration of inactivated influenza vaccine and two post-vaccination time points. Evaluation of new or worsening imAEs occurred via patient questionnaire and review of medical records for 60 days following inactivated influenza vaccination. Baseline imAEs were evaluated from review of medical records for 60 days prior to inactivated influenza vaccination. Serum cytokines and chemokines were measured using a multiplex Luminex assay. Results Twenty-four patients were enrolled in this study. Seven patients experienced any grade imAE (one patient having 2) within 60 days following inactivated influenza vaccination. The majority were Grades 1–2, including rash ( n = 3), hypothyroidism, myalgia, and colitis ( n = 1 each). Two patients experienced severe imAEs (grade 3 nephritis and grade 4 diabetes). No significant changes ( p > 0.05) in serum cytokine or chemokine concentrations were observed. Conclusions Although small, our study suggests that inactivated influenza vaccine may be safely administered to patients receiving immune checkpoint inhibitors. The majority of imAEs following inactivated influenza vaccination were Grades 1-2 and did not require changes in immune checkpoint inhibitor therapy.

show abstract

Immunogenicity and safety of influenza vaccination in cancer patients receiving checkpoint inhibitors targeting PD-1 or PD-L1

et al. 2020

View full text Add to dashboard Cite

Impact of the influenza vaccination on cancer patients undergoing therapy with immune checkpoint inhibitors (ICI).

Cited by 11 publications

References 0 publications

State of the art about influenza vaccination for advanced cancer patients receiving immune checkpoint inhibitors: When common sense is not enough

State of the art about influenza vaccination for advanced cancer patients receiving immune checkpoint inhibitors: When common sense is not enough

Immune-mediated adverse events following influenza vaccine in cancer patients receiving immune checkpoint inhibitors

Immunogenicity and safety of influenza vaccination in cancer patients receiving checkpoint inhibitors targeting PD-1 or PD-L1

Contact Info

Product

Resources

About